Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Laura Solmonese"'
Autor:
Maria Fortunata Lofiego, Francesca Piazzini, Francesca Pia Caruso, Francesco Marzani, Laura Solmonese, Emma Bello, Fabrizio Celesti, Maria Claudia Costa, Teresa Noviello, Roberta Mortarini, Andrea Anichini, Michele Ceccarelli, Sandra Coral, Anna Maria Di Giacomo, Michele Maio, Alessia Covre, The EPigenetic Immune-oncology Consortium Airc (EPICA) investigators
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Background Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumor, that is refractory to standard treatment and to immunotherapy with immune-checkpoint inhibitors (ICI). Noteworthy, melanoma brain metastases (MM-BM), that s
Externí odkaz:
https://doaj.org/article/de9304cb7f1e45d7b01e1059c5afd11b
Autor:
Ornella Cutaia, Michele Maio, Luana Calabro, Alessia Covre, Carolina Fazio, Sara Cannito, Health Biology, Maria Fortunata Lofiego, Francesca Piazzini, Laura Solmonese
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/61de23d0000a4cdd84fb55fe3ea34b8a
Autor:
Maria Fortunata Lofiego, Sara Cannito, Carolina Fazio, Francesca Piazzini, Ornella Cutaia, Laura Solmonese, Francesco Marzani, Carla Chiarucci, Anna Maria Di Giacomo, Luana Calabrò, Sandra Coral, Michele Maio, Alessia Covre, on behalf of the EPigenetic Immune-Oncology Consortium Airc (EPICA) Investigators
Publikováno v:
Epigenomes, Vol 5, Iss 4, p 27 (2021)
Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a severe prognosis, and with a long-standing need for more effective therapeutic approaches. However, treatment with immune checkpoint inhibitors is becoming an increasingly effect
Externí odkaz:
https://doaj.org/article/4873e483dc294f2192f580253fb9978d
Autor:
Sara Cannito, Health Biology, Ornella Cutaia, Carolina Fazio, Maria Fortunata Lofiego, Francesca Piazzini, Laura Solmonese, Luana Calabrò, Michele Maio, Alessia Covre
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Growing evidence are demonstrating the therapeutic efficacy of immune checkpoint inhibitors (ICI) in mesothelioma; however, a limited percentage of patients benefits from this therapeutic approach. Epigenetic modifications play a relevant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::917cb8138227eb6d5531deed25b8f756
https://doi.org/10.1136/jitc-2020-sitc2020.0844
https://doi.org/10.1136/jitc-2020-sitc2020.0844